Octreotide
Common brands: Sandostatin Lar Depot, Sandostatin, Octreotide, Mycapssa, Afinitor Disperz
Top reporter: Novartis Pharmaceuticals Corporation
Somatostatin Analog [EPC]Kinase Inhibitor [EPC]mTOR Inhibitor Immunosuppressant [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
30,228
Total Reports
13,009
Serious Reports
6,077
Death Reports
30
Reported Reactions
Death Report Ratio: High (20.10%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Octreotide.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DIARRHOEA | 4,524 | |
| 2 | DEATH | 4,169 | |
| 3 | FATIGUE | 3,497 | |
| 4 | MALAISE | 3,001 | |
| 5 | BLOOD PRESSURE INCREASED | 2,966 | |
| 6 | NAUSEA | 2,943 | |
| 7 | NEEDLE ISSUE | 2,773 | |
| 8 | PAIN | 2,575 | |
| 9 | ABDOMINAL PAIN | 2,458 | |
| 10 | MALIGNANT NEOPLASM PROGRESSION | 2,458 | |
| 11 | BLOOD PRESSURE SYSTOLIC INCREASED | 2,386 | |
| 12 | ASTHENIA | 2,267 | |
| 13 | WEIGHT DECREASED | 2,264 | |
| 14 | INJECTION SITE PAIN | 2,186 | |
| 15 | HEADACHE | 2,065 | |
| 16 | VOMITING | 2,036 | |
| 17 | DIZZINESS | 2,028 | |
| 18 | DRUG INEFFECTIVE | 1,978 | |
| 19 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 1,940 | |
| 20 | FALL | 1,796 | |
| 21 | DYSPNOEA | 1,671 | |
| 22 | OFF LABEL USE | 1,648 | |
| 23 | ARTHRALGIA | 1,642 | |
| 24 | BACK PAIN | 1,495 | |
| 25 | PAIN IN EXTREMITY | 1,461 | |
| 26 | BODY TEMPERATURE DECREASED | 1,454 | |
| 27 | PYREXIA | 1,382 | |
| 28 | COUGH | 1,380 | |
| 29 | DECREASED APPETITE | 1,367 | |
| 30 | ABDOMINAL PAIN UPPER | 1,260 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.